Skip to main content
ProGen, Co,, LTD. logo

ProGen, Co,, LTD. — Investor Relations & Filings

Ticker · 296160 ISIN · KR7296160005 KO Manufacturing
Open in API
Filings indexed 153 across all filing types
Latest filing 2026-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 296160

About ProGen, Co,, LTD.

https://progen.co.kr

ProGen is an R&D-focused biopharmaceutical company dedicated to developing innovative drugs for incurable diseases, with a primary focus on oncology, immune diseases, and metabolic disorders. The company specializes in creating novel protein-based immunotherapies and antibody therapeutics. Its research and development efforts are driven by proprietary technology platforms, including the NTIG (Neo Tri-ImmunoGlobulin) platform for next-generation multi-specific fusion proteins and the hyFc® platform for long-acting fusion proteins. These technologies enable the engineering of advanced bi-specific and multi-specific therapies designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by ProGen. It details the date, location, agenda items (such as approval of financial statements, election of directors, and remuneration limits), and provides biographical details for director nominees. This document is a standard proxy solicitation/information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2026-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for ProGen Co., Ltd. It contains the agenda for the upcoming Annual General Meeting (AGM), including reports on financial statements, director appointments, and proposed changes to the articles of incorporation. It also includes detailed management information, such as board activity, director remuneration, and financial statements (balance sheet, income statement, etc.) as required for shareholder review prior to the meeting. This type of document is standard for proxy solicitation and shareholder information materials provided ahead of an AGM.
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients and the total number of shares granted. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically identified as a '정정신고' (Amendment Report). It details changes to the number of stock options granted, the list of recipients, and the total number of shares involved due to employee departures and cancellations. This type of filing is a standard regulatory disclosure regarding capital structure and equity compensation, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance).
2026-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to the number of stock options granted due to employee departures. This type of filing, which concerns changes in capital structure and equity-based compensation, falls under the category of regulatory filings regarding share-related changes. Since it is a specific regulatory disclosure of a corporate action (stock option amendment) rather than a general announcement or a report publication, it is best classified as a Regulatory Filing (RNS) as it does not fit into the more specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance).
2026-02-05 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고 정정신고' (Amendment to the Report on Granting Stock Options). It details changes to previously reported stock option grants, including the number of recipients and the total number of shares, due to employee departures. This type of filing is a standard regulatory disclosure regarding capital structure and equity compensation, which falls under the 'Regulatory Filings' category as it is a specific corporate announcement to the financial authorities.
2026-02-05 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.